Compare HRL & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRL | KYMR |
|---|---|---|
| Founded | 1891 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 9.0B |
| IPO Year | 1994 | 2020 |
| Metric | HRL | KYMR |
|---|---|---|
| Price | $21.89 | $132.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 24 |
| Target Price | $25.31 | ★ $144.57 |
| AVG Volume (30 Days) | ★ 4.7M | 893.7K |
| Earning Date | 12-03-2026 | 10-29-2026 |
| Dividend Yield | ★ 5.18% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $12,106,160,000.00 | $39,211,000.00 |
| Revenue This Year | $0.07 | $153.53 |
| Revenue Next Year | $1.95 | N/A |
| P/E Ratio | $31.60 | ★ N/A |
| Revenue Growth | ★ 1.55 | N/A |
| 52 Week Low | $18.96 | $58.87 |
| 52 Week High | $26.60 | $136.57 |
| Indicator | HRL | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 59.31 | 65.27 |
| Support Level | $20.38 | $104.96 |
| Resistance Level | $22.03 | N/A |
| Average True Range (ATR) | 0.47 | 7.07 |
| MACD | 0.22 | 1.97 |
| Stochastic Oscillator | 59.56 | 78.38 |
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and became a branded food company. The firm sells its wares through multiple channels, including US retail (61.6% of fiscal 2025 sales), US foodservice (32.6%), and international (less than 6%). By product, 73% of fiscal 2025 sales were from perishable food and 27% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.